Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
29 March 2023 - 9:00PM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, today announced it
ranked No. 2 on the Financial Times 2023 list of the fastest
growing companies in the Americas. This follows the company’s No. 1
ranking on the 2022 list.
Companies were ranked based on the compound annual growth rate
of their revenue from 2018 to 2021. Axonics reported $180.3 million
of revenue in fiscal year 2021 compared to $707,000 in fiscal year
2018, representing a compound annual growth rate of 534%.
“Axonics is proud to once again be recognized as one of the
fastest growing companies in the Americas,” said Raymond W. Cohen,
chief executive officer. “The strong growth of Axonics is a
testament to the dedication of our employees and a commitment to
continuous innovation. We have built a company that values and
rewards quality, integrity, teamwork and first-class customer
support. We are working diligently to increase public awareness
that urinary incontinence is not a normal part of aging and that
Axonics has best-in-class therapies proven to significantly improve
the quality of life for adults with bladder and bowel
dysfunction.”
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 2 on the
2023 Financial Times ranking of the fastest growing companies in
the Americas and No. 4 on the 2022 Deloitte Technology Fast
500.
Axonics® sacral neuromodulation systems provide adults with
overactive bladder and/or fecal incontinence with long-lived, easy
to use, safe, clinically effective therapy. In addition, the
company’s best-in-class urethral bulking hydrogel, Bulkamid®,
provides safe and durable symptom relief to women with stress
urinary incontinence. In the U.S., moderate to severe urinary
incontinence affects an estimated 28 million women and fecal
incontinence affects an estimated 19 million adults. Axonics’
clinically proven products are offered at hundreds of medical
centers across the U.S. and abroad. Reimbursement coverage is well
established in the U.S. and is a covered service in most European
countries. For more information, visit www.axonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230329005429/en/
Neil Bhalodkar 949-336-5293 IR@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Apr 2023 to Apr 2024